期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
肿瘤标志物类定量检测试剂注册申报临床研究技术要求 被引量:1
1
作者 李耀华 《中华检验医学杂志》 CAS CSCD 北大核心 2011年第12期1168-1170,共3页
肿瘤标志物( tumor marker,TM)是指在恶性肿瘤发生和增殖过程中,由肿瘤细胞产生或机体反应而异常产生和(或)升高的,反映肿瘤细胞特性的一类物质,如癌胚抗原(carcinoembryonic antigen,CEA)、甲胎蛋白(alpha fetoprotein,AFP)、... 肿瘤标志物( tumor marker,TM)是指在恶性肿瘤发生和增殖过程中,由肿瘤细胞产生或机体反应而异常产生和(或)升高的,反映肿瘤细胞特性的一类物质,如癌胚抗原(carcinoembryonic antigen,CEA)、甲胎蛋白(alpha fetoprotein,AFP)、前列腺特异性抗原(prostate specific antigen,PSA)等[1-3].目前,TM在临床上主要用于对经过组织学确诊的恶性肿瘤患者进行病情的动态监测,TM浓度的逐渐升高常意味着疾病处于不断进展期或现行治疗措施的效果不佳,浓度降低则意味着对治疗有反应或疗效较好,而稳定的抗原水平则常常暗示疾病处于稳定期.动态监测的另一目的是判断残留病灶、预测复发,TM浓度持续低水平升高意味着可能有残留病灶的存在,而短期内迅速升高则往往是疾病复发的前兆[2-5]. 展开更多
关键词 肿瘤标志物类 临床研究 检测试剂 前列腺特异性抗原 恶性肿瘤患者 申报 注册 MARKER
原文传递
胎盘型谷胱苷肽S转移酶——一种新的肿瘤标志物 被引量:19
2
作者 梁晓秋 《国外医学(生理病理科学与临床分册)》 1997年第1期41-44,共4页
自从发现胎盘型谷胱甘肽S转移酶(GST-π)为大鼠肝脏化学致癌中敏感的癌前标志酶以来,现已证实在许多人体肿瘤中表达增加,尤其是胃肠道癌及癌前病变,病变与GST-πmRNA水平表达一致,还与肿瘤化疗的耐药性密切相关。因... 自从发现胎盘型谷胱甘肽S转移酶(GST-π)为大鼠肝脏化学致癌中敏感的癌前标志酶以来,现已证实在许多人体肿瘤中表达增加,尤其是胃肠道癌及癌前病变,病变与GST-πmRNA水平表达一致,还与肿瘤化疗的耐药性密切相关。因此,GST-π可作为一种新的肿瘤标志物,用于一些肿瘤的早期诊断及为肿瘤的化疗提供指导。 展开更多
关键词 谷胱甘肽转移酶 肿瘤标志物类 生物
下载PDF
ZNF217 expression correlates with the biological behavior of human ovarian cancer cells 被引量:1
3
作者 Lilin Hang Min Zhang +2 位作者 Fanliang Meng Mei Zhong Jing Li 《The Chinese-German Journal of Clinical Oncology》 CAS 2014年第11期539-544,共6页
The aim of the study was to investigate the correlation of zinc-finger protein 217 (ZNF217) gone ex- pression with the biological behavior of human ovarian cancer HO-8910 cells. Methods: The expression of ZNF217 in... The aim of the study was to investigate the correlation of zinc-finger protein 217 (ZNF217) gone ex- pression with the biological behavior of human ovarian cancer HO-8910 cells. Methods: The expression of ZNF217 in ovarian carcinoma cell line:s was detected by RT-PCR and Western blot, respectively. The biological behaviors of the transfectants were investigated by MTT, in vitro Boyden chamber and in vivo invasion assay, respectively. Results: RT-PCR and Western blotting revealed that transfection of ZNF217 into the HO-8910 cells significantly increased their proliferation along with mark- edly enhanced in vitro and in vivo invasion and metastatic abilities. MTT assay showed that the proliferation ability of pEGFP- N1-ZNF217/HO-8910 cells was significantly higher than that of pEGFP-N1/HO-8910 cells and HO-8910 cells (P 〈 0.001). The Boyden chamber assay showed that the numbers of migrating pEGFP-N1-ZNF217/HO-8910, pEGFP-N1/HO-8910 and HO-8910 cells were (141.25 ± 13.91) cells/200 x field, (82.50 ± 11.73) cells/200 × field and (81.75 ± 12.12) cells/200 x field, respectively, with a significant difference between them (F = 29.274, P 〈 0.001). The nude mouse experiment showed that the in vivo tumor formation ability of pEGFP-N1-ZNF217/HO-8910 cells was significantly higher than that of pEGFP-N1/HO-8910 cells (P 〈 0.001). Conclusion: Based on these clinical and laboratory observations, we conclude that ZNF217 may contribute to ovarian cancer invasion and metastasis, and associated with worse clinical outcomes. We evaluated ZNF217's role as a biomarker of ovarian carcinogenesis and tumor progression in patient samples and explored possible molecular mechanisms in promoting tumor growth and invasion. 展开更多
关键词 ovaran cancer zinc-finger protein 217 (ZNF217) gene gene expression PROLIFERATION INVASION tumor metastasis
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部